France’s biggest pharmaceutical company to give the US preferential treatment over vaccines

France’s biggest pharmaceutical company to give the US preferential treatment over vaccines.

THE French pharmaceutical giant Sanofi has said that the US will have priority access to a Covid-19 vaccine if and when it develops one as the US offered more money to fund vaccine research.

“The US government has the right to the largest pre-order because it’s invested in taking the risk,” said Sanofi’s Chief Executive Officer Paul Hudson.

Sanofi is one of the biggest among dozens of companies racing to develop a vaccine against the disease and it has partnered with UK rival GlaxoSmithKline Plc on the project supported by the US.

More than 90 vaccines are currently being developed against the disease, but experts say the large-scale manufacture of a successful vaccine may be as challenging as developing one.

The European Commission is weighing using a €2 billion emergency fund to boost pharmaceutical labs’ capacity, fearing that even if a Covid-19 vaccine is developed the EU may not be able to produce enough shots.

The head of Sanofi warned the EU in April that in the current pandemic the manufacturing of vaccines posed more challenges than their actual development.

“There is less concern about finding a successful vaccine than there is about making the volumes needed,” Hudson said.

Estimating production capacity needs is hard because nobody yet knows the composition of a potential Covid-19 shot or how many doses would be needed per person.

As vaccine production is limited, most states agree that a potential Covid-19 shot should initially be made available only to the elderly and other groups most vulnerable to the disease. Medics and nurses would also be on the priority list.

A sudden surge in vaccine demand caused by the development of a Covid-19 shot could put labs under extreme strain and also reduce the availability of other vaccines.

At a meeting last week, EU health experts discussed joining forces to buy flu shots before the next influenza season, “which is even more important due to the ongoing Covid-19 pandemic,” according to public minutes.

Discussions over joint procurement schemes for vaccines highlight the EU’s anxiety over its limited access to vital medical supplies, and the risk that EU states might otherwise bid against each other for access.

Many countries experienced shortages of medical equipment, devices and drugs to treat Covid-19 patients in March and April, and the EU fears shortages could occur again when a Covid-19 vaccine is available.

FacebookTwitterRedditWhatsAppTelegramLinkedInEmailCopy Link
Go Back
Written by

Damon Mitchell

From the interviewed to the interviewer

As frontman of a rock band Damon used to court the British press, now he lives the quiet life in Spain and seeks to get to the heart of the community, scoring exclusive interviews with ex-pats about their successes and struggles during their new life in the sun.

Originally from Scotland but based on the coast for the last three years, Damon strives to bring the most heartfelt news stories from the spanish costas to the Euro Weekly News.

Share your story with us by emailing [email protected], by calling +34 951 38 61 61 or by messaging our Facebook page www.facebook.com/EuroWeeklyNews

Comments


    Leave a comment

    Your email address will not be published.